小児性狼性腎炎におけるミコフェノール酸の露出を予測する: 3つの臨床シナリオにおける現実世界の研究
Baojing Liu1,2, Lizhi Chen3, Yuqi Wang1
1Department of Pharmacy, the First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China.
Rheumatology (Oxford, England)
|February 17, 2026
まとめ
機械学習モデルは,小児性狼性腎炎におけるミコフェノール酸暴露を予測し,治療を最適化します. このフレームワークは,よりよい患者の結果のために,投与戦略をパーソナライズすることによって,精密医療を向上させます.
科学分野:
- ファルマコキネティクスとファルマコダイナミクス
- 医学における機械学習
- 小児腎臓病理学について
背景:
- 乳児期発症性全身性白血球性狼 (cSLE) と白血球性腎炎 (LN) は,治療上の課題を提起しています.
- マイコフェノール酸 (MPA) 製薬動態は,小児性LN患者において複雑である.
- MPAの治療薬モニタリング (TDM) には限界があります.
研究 の 目的:
- 集中時間曲線 (MPA-AUC) 下のMPA面積を予測するために,機械学習 (ML) モデルを開発します.
- 治療ウィンドウの達成,正確なAUC推定,および用量調整後の曝露予測のためのモデルを評価する.
- 小児性LNの個別化されたMPA投与枠組を確立する.
主な方法:
- ルーティン治療と用量調整コホートにおける154人の小児性LN患者からデータを収集した.
- XGBoost,LightGBM,およびランダムフォレスト (RF) を含むMLアルゴリズムを使用しました.
- モデル解釈性のためにShapley Additive Explanations (SHAP) を利用し,Webベースの臨床意思決定ツールを開発しました.
主要な成果:
- LightGBMモデルは,治療ウィンドウの達成率 (F1=0.65) を予測するのに優れていた.
- RFモデルは,臨床データと濃度を使用して,正確なAUC推定 (R2=0.84) で高い精度を達成しました.
- RFモデルは,用量調整後の曝露の予測能力を実証した (R2=0.51).
- SHAP分析では,投与量,体重,腎機能,および濃度の時間点を主要な予測指標として特定しました.
結論:
- この研究は,小児性LNにおけるパーソナライズされたMPA投与のための最初のML主導のフレームワークを提示しています.
- このアプローチは,TDMの限界に対処し,cSLE患者の精密医療を強化します.
- 開発されたモデルとツールは,最適化されたMPAの治療薬モニタリングと臨床意思決定をサポートすることができます.
関連する概念動画
Pharmacokinetics in Pediatric Patients: Drug Excretion
289
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
289
Pharmacokinetics in Pediatric Patients: Drug Metabolism
258
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
258
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
334
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
334
Pharmacokinetics in Pediatric Patients: Drug Distribution
338
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
338
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
212
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
212
Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant
241
In patients with renal disease, dosage adjustments are necessary to maintain therapeutic plasma drug concentrations and prevent toxicity or subtherapeutic exposure. Renal impairment alters drug pharmacokinetics, especially in conditions like uremia, where changes such as prolonged elimination half-life and altered apparent volume of distribution can significantly affect drug disposition. These changes require careful modification of the dosing regimen to achieve the desired clinical...
241


